MLTX Key Statistics, Chart & Performance
The current stock price of MLTX is 15.67 USD. In the past month the price increased by 18.89%. In the past year, price decreased by -65.93%.
MLTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MLTX. When comparing the yearly performance of all stocks, MLTX is a bad performer in the overall market: 73.74% of all stocks are doing better.
MLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLTX. While MLTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
MLTX Financial Highlights
Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS decreased by -157.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.8% | ||
| ROE | -72.86% | ||
| Debt/Equity | 0.26 |
MLTX Forecast & Estimates
24 analysts have analysed MLTX and the average price target is 19.92 USD. This implies a price increase of 27.13% is expected in the next year compared to the current price of 15.67.
MLTX Ownership
About MLTX
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG CH
Employees: 100
Phone: 41415108022
MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ
Can you describe the business of MOONLAKE IMMUNOTHERAPEUTICS?
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Can you provide the latest stock price for MOONLAKE IMMUNOTHERAPEUTICS?
The current stock price of MLTX is 15.67 USD. The price decreased by -3.33% in the last trading session.
Does MOONLAKE IMMUNOTHERAPEUTICS pay dividends?
MLTX does not pay a dividend.
How is the ChartMill rating for MOONLAKE IMMUNOTHERAPEUTICS?
MLTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for MOONLAKE IMMUNOTHERAPEUTICS?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) currently has 100 employees.
What is the ownership structure of MOONLAKE IMMUNOTHERAPEUTICS (MLTX)?
You can find the ownership structure of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) on the Ownership tab.
Can you provide the short interest for MLTX stock?
The outstanding short interest for MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 8.97% of its float.